Short Interest in Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Decreases By 85.7%

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the recipient of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 100 shares, a drop of 85.7% from the October 15th total of 700 shares. Based on an average daily volume of 3,500 shares, the short-interest ratio is presently 0.0 days.

Santen Pharmaceutical Trading Up 1.5 %

Shares of Santen Pharmaceutical stock traded up $0.16 during trading on Wednesday, hitting $10.78. The stock had a trading volume of 1,357 shares, compared to its average volume of 6,332. Santen Pharmaceutical has a 12 month low of $8.72 and a 12 month high of $13.00. The business’s 50-day moving average is $12.06 and its 200 day moving average is $11.29.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.